The popularity of semaglutide, the active ingredient in Ozempic and Wegovy, has skyrocketed in recent years. Those considering semaglutide for weight loss treatment may wonder about dosing and how ...

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

Novo Nordisk defends its obesity drug CagriSema despite disappointing late-stage trial data that significantly affected its market value. The company plans a new trial in 2025 due to positive ...